IDL Diagnostics (IDLDX) Q2 2026 earnings summary

Executive summary

• Revenue grew by 43.5% year-over-year in Q2 2026, with gross margin rising to 59.9% from 47.3%.

• New CEO Gustav Sten took office on May 28, 2026, after eight years with the company.

• Urology segment sales increased by 50% and infectious diseases by 32% compared to Q2 2025.

• Strategic focus on international expansion, especially in Asia, and preparation for new product launches in China.

Financial highlights

• Q2 2026 revenue: SEK 14,556 thousand (Q2 2025: SEK 10,143 thousand).

• Gross profit: SEK 8,715 thousand (Q2 2025: SEK 4,795 thousand); gross margin: 59.9% (47.3%).

• Operating loss: SEK -1,094 thousand (Q2 2025: SEK -5,045 thousand).

• Net loss: SEK -1,076 thousand (Q2 2025: SEK -5,081 thousand).

• Cash and cash equivalents at June 30, 2026: SEK 35,314 thousand (June 30, 2025: SEK 44,265 thousand).

Outlook and guidance

• Strong order intake and robust demand expected to support future growth.

• Continued focus on expanding presence in prioritized markets and launching new products in China.

• Market for cancer diagnostics projected to reach USD 34.97 billion by 2034, with a CAGR of 6.0%.